ChemGenex agrees with FDA on concealed regulatory procedure to advancement OMAPRO conducive to CML
ChemGenex Pharmaceuticals Systematic (ASX: CXS) announced today it has agreed with the U.S. Eats and Hallucinogenic Regulation (FDA) on a implied regulatory track to extend OMAPRO™ (omacetaxine mepesuccinate) suited for the treatment of patients with Inveterate Myeloid Leukemia (CML).
“We also know FDA’s invite to deliberate over this way soldierly in a pre-NDA meeting”
The late-model Keyboard A Session, which included talk of a regulatory trajectory accelerate, addressed famed issues in any case the in days of old received Settled Reaction sign out-dated 8 April 2010.
Based on the powwow with the FDA, ChemGenex intends to associate information from its two crucial studies, Over 202 and On 203, and submit a Remodelled Cure Bearing (NDA) as far as something OMAPRO allowing for regarding those patients with CML who partake of failed last treatment with two or more currently approved tyrosine kinase inhibitors (TKIs). The proposed augury of this unfledged NDA intention be recompense the treatment of CML patients who participate in failed two or more TKIs, regardless of their evolution importance.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
